1. Adrian Bot joins RNAC's Board, enhancing expertise in immune engineering. 2. Dr. Bot's experience includes leadership in CAR T cell therapies. 3. Cartesian's lead asset, Descartes-08, is in Phase 3 for myasthenia gravis. 4. Focus on advancing the pipeline and exploring new therapy opportunities. 5. The company aims to expand cell therapies for autoimmune diseases.
FAQ
Why Bullish?
The appointment of Dr. Bot is likely to bolster RNAC's clinical strategy, similar success seen when Kite Pharma's leadership led to significant advancements in CAR T therapies.
How important is it?
Dr. Bot's extensive background can lead to innovative therapy advancements, improving RNAC's market position.
Why Long Term?
Expert involvement typically has a delayed effect on stock performance, particularly in biotech development timelines.
Cartesian Therapeutics Appoints Adrian Bot to Board of Directors
FREDERICK, Md., December 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a clinical-stage biotechnology firm focused on innovative cell therapies for autoimmune diseases, has announced the appointment of Adrian Bot, M.D., Ph.D., to its Board of Directors. Dr. Bot brings over 30 years of experience in research and development (R&D) within the biopharma sector, specializing in immune, cell, gene therapy, and nanomedicines. He will serve on the Science and Technology Committee of the Board.
Dr. Bot's Expertise and Industry Impact
“Dr. Bot brings a unique perspective shaped by pioneering work in first-in-class CAR T cell therapies," stated Carsten Brunn, Ph.D., President and CEO of Cartesian Therapeutics. "His recent involvement in the historic acquisition of Capstan’s novel in-vivo CAR T technology by AbbVie, along with his extensive work in RNA-based precision medicines, makes him a valuable addition to our team. We look forward to leveraging his insights as we advance our current pipeline and explore new avenues in cell therapy.”
Dr. Bot's Vision for Cartesian Therapeutics
Dr. Bot expressed enthusiasm for his new role, stating, “Cartesian is at the forefront of expanding cell therapies to treat autoimmunity. We are developing a distinct technology with promising clinical activity and a favorable safety profile. I am eager to contribute my expertise in immune engineering and collaborate with the talented leadership team as we execute our mission.”
Dr. Bot's Professional Background
Before joining Cartesian, Dr. Bot served as the founding Chief Scientific Officer and Executive Vice President of R&D at Capstan Therapeutics, focusing on next-generation RNA-based precision medicines. He also held significant leadership positions at Kite Pharma and Kite, a Gilead Company, where he was instrumental in the development of pioneering CAR T cell therapies for cancer. Dr. Bot has co-authored over 200 peer-reviewed manuscripts and holds an M.D. from the University of Medicine and Pharmacy in Timisoara, Romania, and a Ph.D. in Biomedical Sciences from Mount Sinai School of Medicine.
About Cartesian Therapeutics and Future Prospects
Cartesian Therapeutics is at the leading edge of clinical-stage biotechnology, specializing in cell therapy for autoimmune diseases. The company’s primary asset, Descartes-08, is currently in Phase 3 clinical trials for generalized myasthenia gravis and plans to initiate a Phase 2 trial in myositis. As RNAC continues to innovate in the biotech space, the appointment of Dr. Bot signifies a commitment to advancing therapeutic solutions that address significant unmet medical needs.
Looking Ahead: Key Clinical Trials
Cartesian is focused on the ongoing Phase 3 AURORA trial of Descartes-08, and the upcoming Phase 2 trial in myositis. These trials are critical to determining the efficacy of their therapies and advancing the company's position in the biotechnology sector.
Investor and Media Contacts
- Investor Contact: Megan LeDuc, Associate Director of Investor Relations, megan.leduc@cartesiantx.com
- Media Contact: David Rosen, Argot Partners, david.rosen@argotpartners.com